The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
Abstract
Background The worldwide increase in type 2 diabetes mellitus is becoming a major health concern. We aimed to assess the effect of acarbose in preventing or delaying conversion of impaired glucose tolerance to type 2 diabetes. Methods In a multicentre, placebo-controlled randomised trial, we randomly allocated patients with impaired glucose tolerance to 100 mg acarbose or placebo three times daily. The primary endpoint was development of diabetes on the basis of a yearly oral glucose tolerance test (OGTT). Analyses were by intention to treat. Findings We randomly allocated 714 patients with impaired glucose tolerance to acarbose and 715 to placebo. We excluded 61 (4%) patients because they did not have impaired glucose tolerance or had no postrandomisation data. 211 (31%) of 682 patients in the acarbose group and 130 (19%) of 686 on placebo discontinued treatment early. 221 (32%) patients randomised to acarbose and 285 (42%) randomised to placebo developed diabetes (relative hazard 0.75 [95% CI 0.63-0.90]; p=0.0015). Furthermore, acarbose significantly increased reversion of impaired glucose tolerance to normal glucose tolerance (p Interpretation Acarbose could be used, either as an alternative or in addition to changes in lifestyle, to delay development of type 2 diabetes in patients with impaired glucose tolerance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The DPP and other clinical trials12–16 have established the feasibility of interruption of the worsening of hyperglycaemia in overweight people who have raised fasting or postload glycaemia.”
From 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study (2009) · cites this paper as [14]
In the citing paper
“Acarbose Used adjunctively, acarbose modestly lowers weight ~ 0.5 kg (difference 0·77 kg [95% CI 0·01–1·54] compared to placebo) by delaying carbohydrate absorption and promoting satiety [25].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [25]
In the citing paper
“Studies have shown that the rate of conversion of impaired glucose tolerance to type 2 diabetes mellitus is reduced with lifestyle modification 7 ; the use of metformin, 7 thiazolidinediones, [8][9][10][11] or acarbose 12 ; and bariatric surgery.13”
From Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance (2011) · cites this paper as [12]
In the citing paper
“Furthermore, control of postprandial hyperglycemia with acarbose, an α-glucosidase inhibitor, has been demonstrated to significantly decrease the risk of diabetes in patients with impaired glucose tolerance [56,57].”
From The case for low carbohydrate diets in diabetes management (2005) · cites this paper as [56]
In the citing paper
“Most recently, the STOPNIDDM study showed that in subjects with IGT, the α -glucosidase inhibitor acarbose reduced the risk of developing diabetes by 25% [160].”
From The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes (2003) · cites this paper as [160]
13 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Self-citationReport of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections
King, H., Aubert, R. E., & Herman, W. H. (1998) · Diabetes Care · doi:10.2337/diacare.21.9.1414 · Cited by 6,311
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
DeFronzo, R. A., & Ferrannini, E. (1991) · Diabetes Care · doi:10.2337/diacare.14.3.173 · Cited by 4,535
Pan, X.-R., Li, G.-W., Hu, Y.-H., Wang, J.-X., Yang, W.-Y., An, Z.-X., Hu, Z.-X., Juan-Lin, Xiao, J.-Z., Cao, H.-B., et al. (1997) · Diabetes Care · doi:10.2337/diacare.20.4.537 · Cited by 4,320
Warnick, G. R., Benderson, J., & Albers, J. J. (1982) · Clinical Chemistry · doi:10.1093/clinchem/28.6.1379 · Cited by 2,159
Rossetti, L., Giaccari, A., & DeFronzo, R. A. (1990) · Diabetes Care · doi:10.2337/diacare.13.6.610 · Cited by 770
Research works printed but not linked: 1
- 1985, Diabetes mellitus, WHO Tech Rep Ser, 727, 7
Cited by
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
Alberti, K. G. M. M., Zimmet, P., & Shaw, J. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01858.x · Cited by 6,597
Kernan, W. N., Ovbiagele, B., Black, H. R., Bravata, D. M., Chimowitz, M. I., Ezekowitz, M. D., Fang, M. C., Fisher, M., Furie, K. L., Heck, D. V., et al. (2014) · Stroke · doi:10.1161/str.0000000000000024 · Cited by 5,170
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Metadata
- Authors
- Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., & Laakso, M.
- Affiliations
- Centre Hospitalier de l’Université de Montréal (CA)
- St. Michael's Hospital (CA)
- Sheba Medical Center (IL)
- University of Eastern Finland (FI)
- Corresponding author
- Chiasson, Jean-Louis
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2002-06
- Volume
- 359
- Issue
- 9323
- Pages
- 2072-2077
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2123744385
- Semantic Scholar
- 74e5e0d37131f95910bf094679eb3887f2cee34b
- Cited by
- 2,543
- References
- 26
- Citations by year
- 2026: 30 · 2025: 48 · 2024: 75 · 2023: 69 · 2022: 78 · 2021: 85 · 2020: 90 · 2019: 81 · 2018: 96 · 2017: 84 · 2016: 110 · 2015: 108 · 2014: 116 · 2013: 105 · 2012: 124
- FWCI
- 82.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Keywords
- acarbose, type 2 diabetes prevention, impaired glucose tolerance, alpha-glucosidase inhibitors, diabetes prevention, oral glucose tolerance test, flatulence, diarrhea, lifestyle intervention
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Glucose Intolerance, Acarbose
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. https://app.cochat.ai/papers/10.1016/s0140-6736(02)08905-5
- The paper
- Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., & Laakso, M. (2002). Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. The Lancet. https://doi.org/10.1016/s0140-6736(02)08905-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.